OncoTartis Overview
- Year Founded
-
2011

- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Investors
-
3
OncoTartis General Information
Description
Developer of anti-cancer drugs designed to help patients recover from acute leukemia. The company's drug development approach is designed to develop small molecules for the treatment of malignancies originating from specific tissues that are either non-essential for the general viability of mammalian organisms or can be effectively replaced, enabling patients to have access to novel therapies for the treatment of cancer and white cell diseases.
Contact Information
Website
www.oncotartis.comCorporate Office
- 640 Ellicott Street
- Suite 480
- Buffalo, NY 14203
- United States
Corporate Office
- 640 Ellicott Street
- Suite 480
- Buffalo, NY 14203
- United States
OncoTartis Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
5. Later Stage VC | 11-Dec-2017 | Completed | Clinical Trials - Phase 1 | |||
4. Grant | 07-Jun-2017 | Completed | Generating Revenue | |||
3. Grant | Completed | Generating Revenue | ||||
2. Later Stage VC (Series B) | 01-Jul-2016 | $1.85M | $8.25M | Completed | Generating Revenue | |
1. Early Stage VC (Series A) | 17-Feb-2011 | $6.4M | $6.4M | Completed | Generating Revenue |
OncoTartis Comparisons
Industry
Financing
Details
OncoTartis Competitors (47)
One of OncoTartis’s 47 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
Innovimmune Biotherapeutics | Accelerator/Incubator Backed | New York, NY | ||||
Light Chain Bioscience | Formerly PE-Backed | Geneva, Switzerland | ||||
SystImmune | Venture Capital-Backed | Redmond, WA | ||||
Loxo Oncology | Formerly VC-backed | Stamford, CT |
OncoTartis Patents
OncoTartis Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
AU-2014369926-A1 | Benzamide and nicotinamide compounds and methods of using same | Active | 24-Dec-2013 | ||
AU-2014369926-B2 | Benzamide and nicotinamide compounds and methods of using same | Inactive | 24-Dec-2013 | ||
AU-2019250170-A1 | Benzamide and nicotinamide compounds and methods of using same | Active | 24-Dec-2013 | ||
AU-2019250170-B2 | Benzamide and nicotinamide compounds and methods of using same | Inactive | 24-Dec-2013 | ||
CA-2933632-A1 | Benzamide and nicotinamide compounds and methods of using same | Active | 24-Dec-2013 | C07D471/04 |
OncoTartis Investors (3)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Pharmstandard (Pharmaceuticals) | Corporation | Minority | ||
Startup Village | Government | |||
Skolkovo Foundation | Limited Partner |
OncoTartis FAQs
-
When was OncoTartis founded?
OncoTartis was founded in 2011.
-
Where is OncoTartis headquartered?
OncoTartis is headquartered in Buffalo, NY.
-
What industry is OncoTartis in?
OncoTartis’s primary industry is Drug Discovery.
-
Is OncoTartis a private or public company?
OncoTartis is a Private company.
-
What is OncoTartis’s current revenue?
The current revenue for OncoTartis is
. -
How much funding has OncoTartis raised over time?
OncoTartis has raised $14.2M.
-
Who are OncoTartis’s investors?
Pharmstandard (Pharmaceuticals), Startup Village, and Skolkovo Foundation have invested in OncoTartis.
-
Who are OncoTartis’s competitors?
NexImmune, Innovimmune Biotherapeutics, Light Chain Bioscience, SystImmune, and Loxo Oncology are some of the 47 competitors of OncoTartis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »